Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/22/2025 | $24.00 | Buy | Canaccord Genuity |
| 11/8/2024 | $18.00 → $24.00 | Hold → Buy | Stifel |
| 5/8/2024 | $15.00 → $20.00 | Neutral → Buy | ROTH MKM |
| 10/20/2023 | $12.00 | Neutral | ROTH MKM |
| 9/12/2023 | Buy → Neutral | BTIG Research | |
| 9/12/2023 | Buy → Hold | Stifel | |
| 7/19/2023 | $27.00 | Buy | BTIG Research |
| 3/4/2022 | $41.00 → $45.00 | Hold → Buy | Stifel |
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00
Stifel upgraded Orthofix from Hold to Buy and set a new price target of $24.00 from $18.00 previously
ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously
Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O
Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Orthopedics and Bone Growth Therapies Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 2023, driven by distribution expansion and further penetration in existing account
Company to Host Conference Call on Tuesday, February 25, 2025 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the event passcode 5184023. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Post
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G - Orthofix Medical Inc. (0000884624) (Subject)
SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H
SCHEDULE 13D/A - Orthofix Medical Inc. (0000884624) (Subject)
8-K - Orthofix Medical Inc. (0000884624) (Filer)
8-K - Orthofix Medical Inc. (0000884624) (Filer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port
Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319068728/en/TrueLok™ Elevate Transverse Bone Transport (TBT) System TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue deformities and defects such as diabetic foot ulcers and nonhealing or deep tissue wounds. While the TBT procedure has previously been reported,1 TrueLok Elevat